- Previous Close
86.03 - Open
85.96 - Bid 88.62 x --
- Ask 88.77 x --
- Day's Range
85.88 - 88.77 - 52 Week Range
53.00 - 89.77 - Volume
376,961 - Avg. Volume
943,047 - Market Cap (intraday)
21.089B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Oct 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
105.60
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
www.galderma.com6,545
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GALD.SW
View MorePerformance Overview: GALD.SW
Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GALD.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GALD.SW
View MoreValuation Measures
Market Cap
20.44B
Enterprise Value
22.71B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.33%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.32B
Net Income Avi to Common (ttm)
-14.2M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
385M
Total Debt/Equity (mrq)
38.61%
Levered Free Cash Flow (ttm)
--